You Need to Know About the Top 5 Trends in Pharmaceutical Analysis
Pharmaceutical analysis is advancing to improve drug discovery and safety. Here are five top pharmaceutical trends driving the sector today. Read more [...]
Tag Archives: Pharma
Five Innovative Technologies Improving Pharmaceutical Wastewater Treatment
As people use water in various industrial processes, they tend to pollute it. To protect the environment and ensure people have clean drinking water, people need to treat wastewater. Read more [...]
The future is now: FDA approves first pill with digital sensor
The Internet of Things has been a big buzz word in technology for a couple years now. The Internet of Things refers to how everyday devices are becoming connected or digitised with technology. Who would have thought that pills could be digitised and that prescribed medicines could become part of The Internet of Things? It happened this past November when the FDA (Food and Drug Administration) approved the first pill with a digital sensor. What does this mean for medicine? It means that the prescribing doctor can be notified when a patient takes their medication; or maybe even more importantly, if they didn’t take their medication as prescribed. Read more [...]
Deep risk in pharmaceutical shipping sparks debate
Pharmaceuticals and related components ship across the globe on a daily basis. Due to the nature of the medicines shipped, there are always some risks to consider before, during and after shipment. What are the most common risks that a pharmaceutical Read more [...]
‘Elixir of Youth’ Sparks Clash of Croatian Scientists
A Slovenian company that makes an antioxidant pill some media have dubbed an "elixir of youth" is threatening to file lawsuits against scientists who have publicly spoken out against the product, calling it insufficiently tested. The face-off has an added Read more [...]
Pharma grinding to a hault?
More evidence recently published by the 2011 Pharmaceutical R&D Factbook indicates that the pharma industry's productivity is continuing to decline. Fewer new molecular entities were launched in 2010 than in any other year in the past decade. The number of drugs entering Phase I, II and III clinical trials is also declining. R&D expenditure has also dropped to a three year low of $68 billion. Read more [...]
EuroScientist journal 